nature portfolio

- Accession codes, unique identifiers, or web links for publicly available datasets

- For clinical datasets or third party data, please ensure that the statement adheres to our policy

- A description of any restrictions on data availability

Data is currently available at https://crcns.org/data-sets/pfc/pfc-1

Corresponding author(s):	Joao Barbosa
Last updated by author(s):	23/09/2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics					
For all statistical and	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
☐ ☐ The exact	xact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A stateme	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statist	cical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.				
A descripti	ion of all covariates tested				
A descripti	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	ription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hy Give P value	pothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted as as exact values whenever suitable.				
For Bayesi	an analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierard	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
☐ Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and	d code				
Policy information a	about <u>availability of computer code</u>				
Data collection	n/a				
Data analysis	The code necessary to replicate all figures are available at https://github.com/jmourabarbosa/multi-area-ctx				
,	custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Data					
,	about <u>availability of data</u> ust include a <u>data availability statement</u> . This statement should provide the following information, where applicable:				

Human rese	earch part	icipants
Policy information	about <u>studies</u>	involving human research participants and Sex and Gender in Research.
Reporting on sex	k and gender	n/a
Population chara	acteristics	n/a
Recruitment		n/a
Ethics oversight		n/a
Note that full informa	ation on the app	proval of the study protocol must also be provided in the manuscript.
Field-spe	ecific re	eporting
<u>.</u>		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences		Behavioural & social sciences
For a reference copy of	the document with	h all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces st	udy design
All studies must dis	sclose on these	e points even when the disclosure is negative.
Sample size	deciding the s	rming a novel analyses on a previously collected dataset, so novel experiments were not conducted. We did not play any role in ample size. For a justification of the sample size and general experimental design, we refer the reader to the original study: Weese, Neuron. 2014 Jun 4;82(5):1157-70. doi: 10.1016/j.neuron.2014.04.031.
Data exclusions	n/a	
Replication	n/a	
Randomization	n/a	
Blinding	n/a	
Reportin	ig for s	pecific materials, systems and methods
		s about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, o your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & ex	perimental	systems Methods
n/a Involved in th	,	n/a Involved in the study
Antibodies Antibodies		ChIP-seq Flow cytometry
	logy and archae	
	nd other organis	ms ·
Clinical da		
Dual use r	esearch of conce	erii
Animals and other research organisms		
·	about studies	involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
<u>Research</u>		

Laboratory animals

n/a

Wild animals	n/a
Reporting on sex	n/a
Field-collected samples	n/a
Ethics oversight	n/a

Note that full information on the approval of the study protocol must also be provided in the manuscript.